Your browser doesn't support javascript.
loading
Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
Goschzik, Tobias; Zur Muehlen, Anja; Doerner, Evelyn; Waha, Andreas; Friedrich, Carsten; Hau, Peter; Pietsch, Torsten.
Afiliação
  • Goschzik T; From the Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.
  • Zur Muehlen A; From the Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.
  • Doerner E; From the Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.
  • Waha A; From the Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.
  • Friedrich C; Division of Pediatric Oncology and Hematology, University Children's Hospital Rostock, Rostock, Germany.
  • Hau P; Department of Neurology and Wilhelm Sander NeuroOncology Unit, Regensburg University Hospital, Regensburg, Germany.
  • Pietsch T; From the Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany.
J Neuropathol Exp Neurol ; 80(5): 419-430, 2021 04 16.
Article em En | MEDLINE | ID: mdl-33870422
ABSTRACT
Adult medulloblastomas (MB) are rare. We investigated the genetic landscape and prognostic impact of genetic aberrations in a cohort of 117 adult medulloblastomas. Histological features and pathway activation were evaluated at the protein level; 14.5% showed wingless-type activation, 63.3% SHH activation, and 22.2% were classified as non-WNT/non-SHH-MB. Genome-wide copy number analysis was performed by molecular inversion probe array technology. MB-related genes were sequenced in WNT- and SHH-activated MBs. 79.7% of SHH-MBs showed desmoplastic/nodular histology; all other MBs had classic histology. WNT-MBs carried oncogenic CTNNB1 mutations in 88.2% and had monosomy 6 in 52.9%. In SHH-MBs, TERT promoter mutations occurred in 97%, mutations in PTCH1 in 38.2%, SMO in 15.5%, SUFU in 7.4%, and TP53-mutations in 4.1%. In all, 84.6% of non-WNT/non-SHH-MBs had an isochromosome 17q. A whole chromosomal aberration (WCA) signature was present in 45.1% of SHH-TP53-wild type (wt)-MBs and 65.4% of non-WNT/non-SHH-MBs. In 98 cases with survival data, WNT-MBs had a 5-year overall survival (OS) of 68.6%. SHH-MBs TP53wt type and non-WNT/non-SHH-MBs showed 5-year OS of 80.4% and 70.8%, respectively. TP53-mutant SHH-MBs represented a prognostically unfavorable entity; all patients died within 5 years. Patients with a WCA signature showed significantly increased OS (p = 0.011 for SHH-TP53wt-MBs and p = 0.048 for non-WNT/non-SHH-MBs).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cerebelares / Citogenética / Meduloblastoma / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Neuropathol Exp Neurol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cerebelares / Citogenética / Meduloblastoma / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Neuropathol Exp Neurol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha